Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Nov 25, 2014 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 10,000 | -- | 550 | |
| Nov 25, 2014 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 10,000 | -- | 20,000 | |
| Nov 25, 2014 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 5,000 | -- | 25,000 | |
| Aug 25, 2014 | VP, Pharmacology & Biology | Open market or private purchase of non-derivative or derivative security | Form 4 | 7,450 | $6.00 | 59,158 | |
| Aug 25, 2014 | VP, Pharmacology & Biology | Open market or private purchase of non-derivative or derivative security | Form 4 | 5,000 | $6.00 | 64,158 | |
| Aug 25, 2014 | VP, Pharmacology & Biology | Open market or private sale of non-derivative or derivative security | Form 4 | 12,450 | $6.00 | 51,708 | |
| Aug 25, 2014 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 7,450 | -- | 10,550 | |
| Aug 25, 2014 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 5,000 | -- | 30,000 | |
| Aug 20, 2014 | VP, Pharmacology & Biology | Open market or private purchase of non-derivative or derivative security | Form 4 | 7,000 | $5.40 | 58,708 | |
| Aug 20, 2014 | VP, Pharmacology & Biology | Open market or private sale of non-derivative or derivative security | Form 4 | 7,000 | $5.40 | 51,708 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.